Elicio Therapeutics (ELTX) Cash & Current Investments (2020 - 2026)

Elicio Therapeutics has reported Cash & Current Investments for 7 years, with the latest figure at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 21.47% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (down 21.47% YoY), and the FY2025 full-year result was $18.6 million, down 1.24% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $14.9 million, down from $18.6 million in the prior quarter.
• The five-year high for Cash & Current Investments was $73.0 million in Q1 2022, with the low at $598000.0 in Q2 2022.
• Historically, Cash & Current Investments has averaged $17.7 million across 5 years, with a median of $16.5 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Current Investments sank 99.49% — and 2023, when it soared 3525.75%.
• Elicio Therapeutics' Cash & Current Investments stood at $7.8 million in 2022, then jumped by 74.63% to $13.6 million in 2023, then jumped by 38.04% to $18.8 million in 2024, then slipped by 1.24% to $18.6 million in 2025, then slipped by 19.47% to $14.9 million in 2026.
• The last three Cash & Current Investments figures came in at $14.9 million (Q1 2026), $18.6 million (Q4 2025), and $20.6 million (Q3 2025), per Business Quant data.